Human Epidermal Growth Factor Receptor 2 Positive

• Human Epidermal Growth Factor Receptor 2 (HER2) is a protein that promotes cell growth, and its overexpression can lead to uncontrolled cell division.
• A cancer is designated as HER2 positive when its cells produce too many HER2 proteins, often making the cancer more aggressive.
• Testing for HER2 status is crucial for diagnosing certain cancers, particularly breast and gastric cancers.
• Knowing a patient’s HER2 status guides the use of targeted therapies, which specifically block HER2 and have significantly improved patient outcomes.
• Targeted treatments for HER2-positive cancers are a cornerstone of modern oncology, offering personalized and effective therapeutic options.

What is Human Epidermal Growth Factor Receptor 2 (HER2) Positive?

Human Epidermal Growth Factor Receptor 2 (HER2) is a protein found on the surface of all cells, playing a vital role in normal cell growth, division, and repair. Its normal human epidermal growth factor receptor 2 function involves receiving signals that tell cells to grow and divide. In a healthy state, HER2 helps maintain the delicate balance of cellular processes.

When a cancer is described as HER2 positive, it means that the cancer cells have an abnormally high number of HER2 receptors on their surface. This overexpression of HER2 proteins acts like an “on switch,” constantly signaling the cells to grow and divide rapidly and uncontrollably. This characteristic is what what does her2 positive mean for a cancer, often leading to more aggressive tumor growth and faster progression if left untreated.

The presence of excess HER2 protein is a defining feature of her2 positive cancer explained, which accounts for approximately 15-20% of breast cancers and a significant portion of gastric and gastroesophageal junction cancers. According to the American Cancer Society, HER2-positive breast cancer, for instance, affects hundreds of thousands of individuals globally each year, highlighting the importance of accurate diagnosis and targeted treatment.

HER2 Positive Status: Implications for Cancer Diagnosis and Treatment

Determining a patient’s HER2 positive status implications is a critical step in cancer diagnosis and treatment planning. This status is typically assessed through laboratory tests performed on tumor tissue samples obtained via biopsy or surgery. The most common methods include immunohistochemistry (IHC), which measures the amount of HER2 protein on the cell surface, and fluorescence in situ hybridization (FISH) or chromogenic in situ hybridization (CISH), which count the number of HER2 gene copies within the cells.

The results of HER2 testing profoundly influence treatment decisions. Cancers that are HER2-positive often respond well to targeted therapies specifically designed to block the HER2 protein. These therapies, such as trastuzumab (Herceptin), pertuzumab (Perjeta), and ado-trastuzumab emtansine (Kadcyla), work by binding to the HER2 receptors on cancer cells, preventing them from receiving growth signals and even marking them for destruction by the immune system. The advent of these targeted treatments has dramatically improved the prognosis for patients with HER2-positive cancers, transforming a previously aggressive subtype into one with highly effective therapeutic options.

Understanding HER2 status allows oncologists to tailor treatment plans, moving beyond conventional chemotherapy to more precise and effective interventions. This personalized approach not only enhances treatment efficacy but also often reduces the side effects associated with broader-acting systemic treatments. The continued research and development in HER2-targeted therapies offer ongoing hope for improved outcomes for patients worldwide.